Literature DB >> 16231389

Rational design and synthesis of highly potent beta-glucocerebrosidase inhibitors.

Xiaoxiang Zhu1, Kamlesh A Sheth, Shihong Li, Hui-Hwa Chang, Jian-Qiang Fan.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16231389     DOI： 10.1002/anie.200502662

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN： 1433-7851            Impact factor:   15.336


× No keyword cloud information.
  18 in total

1.  Imaging of enzyme replacement therapy using PET.

Authors:  Christopher P Phenix; Brian P Rempel; Karen Colobong; Doris J Doudet; Michael J Adam; Lorne A Clarke; Stephen G Withers
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

2.  Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase.

Authors:  Samarjit Patnaik; Wei Zheng; Jae H Choi; Omid Motabar; Noel Southall; Wendy Westbroek; Wendy A Lea; Arash Velayati; Ehud Goldin; Ellen Sidransky; William Leister; Juan J Marugan
Journal:  J Med Chem       Date:  2012-06-08       Impact factor: 7.446

3.  Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease.

Authors:  Wei Zheng; Janak Padia; Daniel J Urban; Ajit Jadhav; Ozlem Goker-Alpan; Anton Simeonov; Ehud Goldin; Douglas Auld; Mary E LaMarca; James Inglese; Christopher P Austin; Ellen Sidransky
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-01       Impact factor: 11.205

4.  Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.

Authors:  Zhanqian Yu; Anu R Sawkar; Lisa J Whalen; Chi-Huey Wong; Jeffery W Kelly
Journal:  J Med Chem       Date:  2007-01-11       Impact factor: 7.446

5.  N4-phenyl modifications of N2-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease.

Authors:  Wenwei Huang; Wei Zheng; Daniel J Urban; James Inglese; Ellen Sidransky; Christopher P Austin; Craig J Thomas
Journal:  Bioorg Med Chem Lett       Date:  2007-08-28       Impact factor: 2.823

6.  1-Deoxynojirimycins with dansyl capped N-substituents as probes for Morbus Gaucher affected cell lines.

Authors:  Richard F G Fröhlich; Richard H Furneaux; Don J Mahuran; Brigitte A Rigat; Arnold E Stütz; Michael B Tropak; Jacqueline Wicki; Stephen G Withers; Tanja M Wrodnigg
Journal:  Carbohydr Res       Date:  2010-04-24       Impact factor: 2.104

7.  Rapid assembly of a library of lipophilic iminosugars via the thiol-ene reaction yields promising pharmacological chaperones for the treatment of Gaucher disease.

Authors:  Ethan D Goddard-Borger; Michael B Tropak; Sayuri Yonekawa; Christina Tysoe; Don J Mahuran; Stephen G Withers
Journal:  J Med Chem       Date:  2012-03-06       Impact factor: 7.446

Review 8.  Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.

Authors:  Kenneth J Valenzano; Richie Khanna; Allan C Powe; Robert Boyd; Gary Lee; John J Flanagan; Elfrida R Benjamin
Journal:  Assay Drug Dev Technol       Date:  2011-06       Impact factor: 1.738

9.  The myo-1,2-Diaminocyclitol Scaffold Defines Potent Glucocerebrosidase Activators and Promising Pharmacological Chaperones for Gaucher Disease.

Authors:  Ana Trapero; Amadeu Llebaria
Journal:  ACS Med Chem Lett       Date:  2011-05-18       Impact factor: 4.345

10.  Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.

Authors:  Juan J Marugan; Wei Zheng; Omid Motabar; Noel Southall; Ehud Goldin; Wendy Westbroek; Barbara K Stubblefield; Ellen Sidransky; Ronald A Aungst; Wendy A Lea; Anton Simeonov; William Leister; Christopher P Austin
Journal:  J Med Chem       Date:  2011-01-20       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.